Cefoperazone-Induced Transaminitis

Clinical Approach and Management

For patients developing transaminitis during cefoperazone therapy, the American College of Clinical Oncology recommends assessing the severity of elevation, with continued monitoring for mild elevations (<3× upper limit of normal) and consideration of discontinuation for elevations >3× upper limit of normal 1
The American College of Clinical Oncology suggests evaluating for other potential causes of transaminitis, including viral hepatitis, alcohol use, and concomitant hepatotoxic medications, and monitoring liver enzymes until normalization after discontinuation of cefoperazone 1
In cases of severe hepatotoxicity (AST or ALT >5× ULN and/or total bilirubin >3× ULN), cefoperazone should be discontinued immediately, and the American Academy of Family Physicians recommends considering hepatology consultation for patients with significant or persistent liver enzyme elevations 1

The American Academy of Family Physicians notes that cephalosporins, including cefoperazone, have a lower risk of hepatotoxicity compared to other antibiotic classes, such as sulfonamides or macrolides 2